Table 1.

Patient information

Group	Immune tolerant	Immune activation	AR	CR	HC
Cases	6	5	3	3	6
Age (years)	34 (21–55)	29 (25–45)	37 (28–45)	47 (45–49)	52 (33–66)
Sex (M/F)	4/2	4/1	2/1	3/0	4/2
Time since HBV diagnosis (years)	14.7 (1.5–27.0)	20 (10–20)	<0.5	10 (1–20)	NA
HBsAg level (IU/mL)	40 636 (5652–69 050)	7881 (833.2–32 970.0)	783 (0–1293)	<0.05	NA
HBV DNA level (log10 IU/mL)	8.328 (8–8.88)	6.761 (5.29–8)	0.9783 (0–2.935)	LDL	NA
ALT (U/L)	36.1 (20–45.7)	232.2 (60–424)	108 (25–192)	18.67 (13–22)	20.8 (11–31)
AST (U/L)	28.7 (19–42)	91.2 (34–129)	44 (21–58)	19 (16–24)	19 (15–27)

ALT, alanine aminotransferase; AR, acute recovery; AST, aspartate transaminase; CR, chronic resolved; F, female; HBsAg, HBV surface antigen; HC, healthy control; LDL, lower detection limit; M, male; NA, not applicable.